NCT03097120View on ClinicalTrials.gov

The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.

PHASE3CompletedINTERVENTIONAL

Enrollment

309

Participants

Timeline

Start Date

January 31, 1995

Primary Completion Date

January 31, 2001

Study Completion Date

January 31, 2001

Conditions

Heart Disease

Interventions

DRUG

0.625 mg of conjugated equine estrogen

one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily

DRUG

0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate

one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily

DRUG

placebo tablets

two placebo tablets daily

Trial Locations (1)

27157

Wake Forest University School of Medicine, Winston-Salem

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT03097120 - The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs. | Biotech Hunter | Biotech Hunter